Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers
P Horak, C Heining, S Kreutzfeldt, B Hutter, A Mock… - Cancer discovery, 2021 - AACR
The clinical relevance of comprehensive molecular analysis in rare cancers is not
established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients …
established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients …
Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role …
K Christofyllakis, JT Bittenbring… - Molecular and …, 2022 - spandidos-publications.com
Precision cancer medicine (PCM) is an emerging paradigm in oncology, which includes
tumour comprehensive genomic profiling (CGP) to enable molecularly guided therapy …
tumour comprehensive genomic profiling (CGP) to enable molecularly guided therapy …
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity
L Möhrmann, M Werner, M Oleś, A Mock… - Nature …, 2022 - nature.com
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is
unclear. Here, we use comprehensive molecular characterization by whole genome/exome …
unclear. Here, we use comprehensive molecular characterization by whole genome/exome …
Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis
R Hoefflin, A Lazarou, ME Hess, M Reiser, J Wehrle… - Cancers, 2021 - mdpi.com
Simple Summary Access to molecular cancer treatments outside of clinical trials is limited
and the benefit of molecular-guided, individualized patient care in patients with cancer …
and the benefit of molecular-guided, individualized patient care in patients with cancer …
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
M Renovanz, SC Kurz, J Rieger, B Walter… - Neuro-Oncology …, 2023 - academic.oup.com
Background The clinical utility of molecular profiling and targeted therapies for neuro-
oncology patients outside of clinical trials is not established. We aimed at investigating …
oncology patients outside of clinical trials is not established. We aimed at investigating …
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog …
TAS-117 is a potent and selective allosteric pan-v-akt murine thymoma viral oncogene
homolog (Akt) inhibitor. We conducted a single-arm single-center phase 2 study of TAS-117 …
homolog (Akt) inhibitor. We conducted a single-arm single-center phase 2 study of TAS-117 …
Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
J Blobner, L Dengler, S Blobner, C Eberle… - Neuro-Oncology …, 2023 - academic.oup.com
Background Targeted therapies have substantially improved survival in cancer patients with
malignancies outside the brain. Whether in-depth analysis for molecular alterations may …
malignancies outside the brain. Whether in-depth analysis for molecular alterations may …
Implementation of precision oncology for patients with metastatic breast cancer in an interdisciplinary MTB setting
E Sultova, CB Westphalen, A Jung, J Kumbrink… - Diagnostics, 2021 - mdpi.com
The advent of molecular diagnostics and the rising number of targeted therapies have
facilitated development of precision oncology for cancer patients. In order to demonstrate its …
facilitated development of precision oncology for cancer patients. In order to demonstrate its …
A retrospective analysis of biliary tract cancer patients presented to the molecular tumor board at the comprehensive cancer center munich
D Zhang, K Dorman, K Heinrich, L Weiss… - Targeted Oncology, 2023 - Springer
Abstract Background and Objective With the rising importance of precision oncology in
biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe …
biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe …
[HTML][HTML] The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives
N van de Kruis, P van der Ploeg, JHC Wilting… - Gynecologic oncology …, 2022 - Elsevier
Objective Clinical efficacy of cytostatic anticancer agents can be determined with the
progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a …
progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a …